In part 6 of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about what health care providers can do for people with type 1.

In part 7 of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about a diabetes vaccine and past efforts to treat those at risk.

In part 8 of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the diagnosis of diabetes in adults, as differentiated from diagnosis in children.

In part 9, the conclusion of this Exclusive Interview, Dr. Carla Greenbaum talks with Diabetes in Control Publisher Steve Freed during the ADA meeting in San Diego, California about the realities of where diabetes research can be in the next five or more years, in relation to a cure as well as other types of treatments.

When a parent finds out that their child has type 1 diabetes all they can think of is getting their glucose under control. After they get used to the changes for the child and the family, they start to look for ways to either minimize the damage diabetes causes, or …

This week, we want to help you simplify your selection of injectables for patients. While most patients often think that an injection is always insulin, we know that is not true. We also have GLP-1 analogs, as well as combinations of these products, so in our Homerun Slides, we make …

So many of my patients who have insulin resistance, type 1 or type 2 diabetes with hyperglycemia and/or obesity have vitamin D or vitamin B12 deficiency. Often they have never had their levels checked or, if they have, were diagnosed with either or both vitamin D deficiency and vitamin B12 deficiency and do not take their prescribed vitamins. Why?

In part 5 of this Exclusive Interview, Dr. Aaron Vinik talks with Diabetes in Control Publisher Steve Freed during the AACE 2017 convention in Austin, Texas about the need to continue research into drugs such as SGLT-2s because breakthroughs may possibly be found in these medications.

In this week's Homerun Slides, medication trial results, long-acting insulins, and treating prediabetes.

Hypertriglyceridemia and low HDL cholesterol, increased risk of type 2 diabetes: Under fasting conditions, the liver of subjects with NAFLD overproduces triglyceride-enriched VLDL particles despite hyperinsulinemia when compared to equally obese subjects without NAFLD. Insulin normally decreases production of VLDL by inhibiting adipose tissue lipolysis, and by directly suppressing hepatic production of VLDL.